Home > Boards > US OTC > Medical - Healthcare >

BioCorRx Inc. (BICX)

BICX RSS Feed
Add BICX Price Alert      Hide Sticky   Hide Intro
Moderator: Pip611, 236T568
Search This Board: 
Last Post: 5/23/2019 2:02:45 PM - Followers: 145 - Board type: Free - Posts Today: 0

 

 

About BioCorRx

Program Overview

BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.

The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.

BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.

Technology

Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.

Learn more about the side effects of naltrexone.

Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.

naltrexone implant

While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.

While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.

The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.

Mission, Vision, Values

Mission

BioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics.

Vision

BioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs.

Values

BioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care.

Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions.

We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery.

Investors Overview

BioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.

More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion).

BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.

Business Model

BioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.

BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate.

Stock Price & Charts

BioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly.

Company Structure Details

  • Legal name: BioCorRx
    Sector: Healthcare
    Industry: Specialized Health Services
    Full Time Employees: 4
    Public Company: SEC Reporting and fully audited
    Symbol: BICX
    Exchange: OTCBB
    Outstanding: 117,800,000
    Authorized: 200,000,000
    CUSIP: 35804J102
    NAICS Code: 623220
    SIC Number: 8093
    Transfer Agent: Columbia Stock Transfer Company, 1869 E. Seltice Way #292, Post Falls, ID 83854 Tel (208) 664-3544
    CIK: 0001443863
    EIN: 26-1972677
    Year End: December 31
    State of incorporation: Nevada
    Products: Alcohol rehabilitation, exclusive naltrexone implant technology
    Address: 601 North Parkcenter Drive, Suite 103, Santa Ana, CA 92705 USA
    Investors: 858-381-4677
    Email: investors@biocorrx.com
    Website: www.biocorrx.com
Watch Jeremy Miller on Fox News!
https://www.youtube.com/watch?v=kVKgWi3_t5Y

<iframe width="560" height="315" src="; frameborder="0" allowfullscreen></iframe>www.youtube.com/embed/xhJrYqsV0VQ

<iframe width="560" height="315" src="https://www.youtube.com/watch?v=kVKgWi3_t5Y" frameborder="0" allowfullscreen></iframe>


 

BICX Chart

Key Executives

Kent Emry - CEO, Director
Brady Granier -COO, Director
Lourdes Felix -CFO, Director
Dr. Jorge Andrade, Jr. - Director
Neil Muller -Co-Founder and President, Director 

Locations
Locations of independently owned clinics using our Fresh Start Program

Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705
714-541-6100
800-916-1099
www.startfreshrecovery.com 
www.stopdrinkingUSA.com

Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)
www.ExecutiveRecovery.net 

Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109
800-985-7574
www.FreshStartPrivateFlorida.com 

Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
402-884-1221
www.startfreshNE.com

Coming Soon!

• San Francisco, California
• Chandler, Arizona
• North Scottsdale, Arizona
• Connecticut

Insider Interview Links

December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO

 

 

BICX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#12199  Sticky Note Scam company BICX issues FALSE AND MISLEADING press 236T568 04/11/19 02:46:18 PM
#7544  Sticky Note VIVITROL is injectable naltrexone produced by Alkermes plc Pip611 09/09/16 05:15:47 PM
#12358   Enjoy! GaryWinthorpe 05/23/19 02:02:45 PM
#12357   TIMBER! 236T568 05/19/19 08:17:33 PM
#12356   Remember that False and misleading $15.00/share price on 236T568 05/19/19 08:14:59 PM
#12355   BICX - $4.16 million Note convertible to 318.million.common.shares 236T568 05/19/19 08:13:13 PM
#12354   BICX- 750 million Common Shares Authorized 236T568 05/19/19 08:11:46 PM
#12353   Any ideas on the progress for FDA approval? big orange 05/19/19 07:47:17 AM
#12352   Remember that False and misleading $15.00/share price on 236T568 05/17/19 02:30:55 PM
#12351   Just so I can prepare emotionally, what day GaryWinthorpe 05/17/19 11:35:56 AM
#12350   TIMBER! 236T568 05/17/19 11:32:14 AM
#12349   Don't know how that's being paid for...more focused GaryWinthorpe 05/17/19 11:08:07 AM
#12348   BICX - $4.16 million Note convertible to 318.million.common.shares 236T568 05/17/19 10:49:35 AM
#12347   BICX- 750 million Common Shares Authorized 236T568 05/17/19 10:41:45 AM
#12346   Here's a question for you-how is the program big orange 05/17/19 10:26:08 AM
#12344   Whoaaah closed up 4.63% to $4.97 and got Stock62 05/16/19 09:14:37 PM
#12343   yeahhhhhhhhh......so anyways, never answered my original question....very tellin GaryWinthorpe 05/16/19 08:46:47 PM
#12342   BICX- 750 million Common Shares Authorized 236T568 05/16/19 07:15:10 PM
#12341   What? I very much understand the difference 236T568 05/16/19 05:18:49 PM
#12340   Huh? Do you seriously not understand the difference between GaryWinthorpe 05/16/19 04:40:58 PM
#12339   Huh? Do you seriously not understand what "Authorized Common 236T568 05/16/19 04:31:23 PM
#12338   Just to clarify...are you suggesting of BICX current GaryWinthorpe 05/16/19 04:22:53 PM
#12337   BICX- 750 million Common Shares Authorized 236T568 05/16/19 04:17:02 PM
#12336   MASSIVE GIANT BICX, presses onward!! Great things happening. telark 05/16/19 12:06:49 AM
#12335   BICX Q1 NIDA grant RISES 1,000% for the GaryWinthorpe 05/15/19 02:54:55 PM
#12334   BICX Q1 Massive $1.8 million Net Loss for 236T568 05/15/19 01:40:31 PM
#12333   BICX Q1 Revenues DROP 59% for the quarter 236T568 05/15/19 01:38:34 PM
#12332   BICX files 10Q for the first quarter ending 236T568 05/15/19 01:35:41 PM
#12331   Oh my! $5.00 low so far today as 236T568 05/13/19 12:39:24 PM
#12330   Oh my, closed at $5.94 up 18.80% today’s high!!! Stock62 05/10/19 09:35:42 PM
#12329   One last time-who pays for the program in Louisiana? big orange 05/09/19 05:08:50 PM
#12328   Curious, when you say that the company is 236T568 05/09/19 03:54:21 PM
#12327   Growing company BICX issues AWESOME AND TRUTHFUL press Joshthebeast24 05/09/19 12:51:35 AM
#12326   BICX 4th QTR Revenues DROP by 69% to 236T568 05/08/19 09:00:37 PM
#12325   Again who pays for it? big orange 05/08/19 07:26:02 PM
#12323   Scam company BICX issues FALSE AND MISLEADING press 236T568 05/08/19 12:04:40 PM
#12322   One of the best and honest companies ever! BanOxy 05/07/19 05:45:44 PM
#12321   Insiders still crooks...one of the shakiest companies I've Thirdeyeblind 05/07/19 04:42:12 PM
#12320   Thanks Big Orange for trying to bring back Kizersosae 05/05/19 10:20:14 AM
#12319   Who pays for it? big orange 05/04/19 02:54:47 PM
#12318   Whoaaaa! $5.25 close up 1.94%. Bid Stock62 05/03/19 10:29:57 PM
#12317   Uh oh! Closed at $5.25 today... GO BICX!!! telark 05/03/19 04:12:52 PM
#12316   Oh the Humanity! $5.25 high so far today! GaryWinthorpe 05/03/19 12:37:46 PM
#12315   Excellent 5/2/19 article, BICX is legit!!! Stock62 05/03/19 09:37:55 AM
#12314   Keep up the great momentum BICX!!! telark 05/03/19 07:56:33 AM
#12313   Great things continue to come with BICX!! In telark 05/03/19 07:54:17 AM
#12312   In case you missed it, here it is telark 05/03/19 07:49:42 AM
#12311   Scam company BICX issues FALSE AND MISLEADING press 236T568 05/03/19 02:40:49 AM
#12310   Oh the humanity, closed up 7.29% to $5.15 Stock62 05/02/19 09:37:31 PM
#12309   Lol Kizersosae 05/02/19 05:21:03 PM
#12308   Oh my! $5.15 high today - how long GaryWinthorpe 05/02/19 03:26:18 PM
#12307   Whoaaaa! $5.15 high so far today! GaryWinthorpe 05/02/19 03:24:16 PM
PostSubject